124i-pu-ad
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02751554)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 124-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- 124i-pu-ad
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04505358 | Phase 2 | Jan 30, 2021 | Samus Therapeutics |
| NCT04311515 | Phase 2 | Apr 24, 2020 | Samus Therapeutics |
| NCT03935568 | Phase 1 | Jun 30, 2019 | Samus Therapeutics |
| NCT03371420 | Early Phase 1 (Phase 1) | Apr 30, 2016 | Cornell University, Memorial Sloan-Kettering Cancer Center, Rockefeller University, Samus Therapeutics, Sponsor GmbH |
| NCT02751554 | N/A | Apr 1, 2016 | Cornell University, Rockefeller University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Samus Therapeutics | For profit | 4 | 4 | 2 | 2016 |
| Cornell University | Academic/Hospital | 2 | 1 | 2 | 2016 |
| Rockefeller University | Academic/Hospital | 2 | 0 | 2 | 2016 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2016 |
5 organizations
Page 1 / 1